It attaches to CD20 proteins on lymphoma cells and to CD3 proteins on T cells, a type of immune cell that can kill cancer cells. When Columvi attaches to CD20 and CD3, this activates the T cells ...
July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...
An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial.
Breast cancer remains the most common malignancy among women and the second-leading cause of cancer-related deaths in the United States. As the fight against this disease evolves, nuclear medicine ...